留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

心脑血管疾病的治疗新策略:激活压力感受性反射

张丽丽 刘爱军 陈磊 宋洪涛

张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略:激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
引用本文: 张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略:激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
Citation: ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002

心脑血管疾病的治疗新策略:激活压力感受性反射

doi: 10.3969/j.issn.1006-0111.2017.04.002

New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy

  • 摘要: 我国心脑血管疾病的发病人数和死亡人数持续升高,动脉压力感受性反射(arterial baroreflex, ABR)功能受损与许多心脑血管疾病(如高血压、心衰等)的发生、发展密切相关。美国CVRx公司研发的Barostim neoTM仪器可以实现慢性刺激颈动脉窦处的压力感受器,激活压力反射,从而降低血压和心率,用于治疗顽固性高血压、心衰、终末期肾损伤等疾病。其治疗疾病的主要机制是抑制交感神经系统和肾素-血管紧张素系统,增强迷走神经的活动,进而改善压力感受性反射敏感性(baroreflex sensitivity, BRS)和心率变异性,恢复关键脏器的结构和功能。
  • [1] GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1459-1544.
    [2] Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA, 2003, 289(19):2560-2572.
    [3] Dauphinot V, Kossovsky MP, Gueyffier F, et al. Impaired baroreflex sensitivity and the risks of new-onset ambulatory hypertension, in an elderly population-based study[J]. Int J Cardiol, 2013, 168(4):4010-4014.
    [4] Grassi G, Seravalle G, Brambilla G, et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension[J]. Int J Cardiol, 2014, 177(3):1020-1025.
    [5] Pinna GD, Maestri R, Capomolla S, et al. Applicability and clinical relevance of the transfer function method in the assessment of baroreflex sensitivity in heart failure patients[J]. J Am Coll Cardiol, 2005, 46(7):1314-1321.
    [6] 苏定冯.动脉压力感受性反射与心血管疾病[M].//苏定冯,缪朝玉,主编.心血管药理学.2版,北京:科学出版社,2010:101-109.
    [7] Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients[J]. Hypertension, 2010, 55(3):619-626.
    [8] Shen MJ, Zipes DP. Interventional and device-based autonomic modulation in heart failure[J]. Heart Fail Clin, 2015, 11(2):337-348.
    [9] Acelajado MC, Calhoun DA. Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment[J]. Cardiol Clin, 2010, 28(4):639-654.
    [10] Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial[J]. J Am Soc Hypertens, 2012, 6(4):270-276.
    [11] Mozaffarian D, Benjamin EJ, Go AS,et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association[J]. Circulation, 2016, 133(4):e38-360.
    [12] Forfar JC. Neuroendocrine activation in congestive heart failure[J]. Am J Cardiol, 1991, 67(12):3C-5C.
    [13] Keivanidou A, Fotiou D, Arnaoutoglou C, et al. Evaluation of autonomic imbalance in patients with heart failure: a preliminary study of pupillomotor function[J]. Cardiol J, 2010, 17(1):65-72.
    [14] Abraham WT, Zile MR, Weaver FA, et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction[J]. JACC Heart Fail, 2015, 3(6):487-496.
    [15] Richards AM, Troughton R, Lainchbury J, et al. Guiding and monitoring of heart failure therapy with NT-ProBNP: concepts and clinical studies[J]. J Card Fail, 2005, 11(5 Suppl):S34-37.
    [16] Collins AJ, Foley RN, Gilbertson DT, et al. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis[J]. Clin J Am Soc Nephrol, 2009, 4 (Suppl 1):S5-11.
    [17] Converse RL, Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure[J]. N Engl J Med, 1992, 327(27):1912-1918.
    [18] Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease[J]. Circulation, 2002, 105(11):1354-1359.
    [19] Beige J, Koziolek MJ, Hennig G, et al. Baroreflex activation therapy in patients with end-stage renal failure: proof of concept[J]. J Hypertens, 2015, 33(11):2344-2349.
    [20] Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?[J]. Kidney Int, 2013, 83(3):377-383.
    [21] Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients[J]. BMJ, 1989, 298(6681):1152-1157.
    [22] Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension[J]. N Engl J Med, 1989, 321(13):868-873.
    [23] Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin[J]. Diabetes Obes Metab, 2006, 8(4):456-465.
    [24] Wallbach M, Lehnig LY, Helms HJ, et al. Long-term effects of baroreflex activation therapy on glucose metabolism[J]. Acta Diabetol, 2015, 52(5):829-835.
    [25] Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease[J]. Curr Hypertens Rep, 2001, 3 (Supp11):S3-S9.
    [26] Lohmeier TE, Iliescu R, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex[J]. Am J Physiol Heart Circ Physiol, 2010, 299(2):H402-H409.
    [27] Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation[J]. J Appl Physiol, 2012, 113(10):1652-1658.
    [28] Alnima T, de Leeuw PW, Tan FE, et al, Rheos Pivotal Trial I. Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension[J]. Hypertension, 2013, 61(6):1334-1339.
    [29] Lohmeier TE, Iliescu R, Liu B, et al. Systemic and renal-specific sympathoinhibition in obesity hypertension[J]. Hypertension, 2012, 59(2):331-338.
    [30] Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial[J]. J Am Soc Hypertens, 2012, 6(2):152-158.
    [31] Bisognano JD, Kaufman CL, Bach DS, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system[J]. J Am Coll Cardiol, 2011, 57(17):1787-1788.
    [32] La Rovere MT, Christensen JH. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs[J]. Vascul Pharmacol, 2015, 71:1-10.
    [33] Gronda E, Seravalle G, Trevano FQ, et al. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction[J]. J Hypertens, 2015, 33(8):1704-1708.
    [34] Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future[J]. Curr Hypertens Rep, 2010, 12(2):61-66.
  • [1] 温萍, 张俊平.  隐丹参酮及其衍生物抗肿瘤活性研究进展 . 药学实践与服务, 2023, 41(4): 207-211. doi: 10.12206/j.issn.2097-2024.202208090
    [2] 彭伟彪, 王婷, 冯旭, 汪家春, 张阵阵, 储智勇.  冬虫夏草提取液抑制破骨细胞分化与缓解去卵巢小鼠骨量流失的研究 . 药学实践与服务, 2023, 41(2): 97-105. doi: 10.12206/j.issn.2097-2024.202105037
    [3] 黄粤琪, 胡静璐, 李祺, 李淼, 谢菲, 杜丽娜, 金义光.  高原肺部疾病的发病机制及治疗药物 . 药学实践与服务, 2022, 40(4): 289-295. doi: 10.12206/j.issn.1006-0111.202111025
    [4] 严啸东, 郭美丽.  黄酮类化合物抗心脑血管缺血性疾病作用的研究进展 . 药学实践与服务, 2022, 40(2): 97-102. doi: 10.12206/j.issn.1006-0111.202111059
    [5] 董家潇, 金永生, 曹莺.  黄芩素抗肿瘤作用及其机制研究新进展 . 药学实践与服务, 2021, 39(1): 9-12, 43. doi: 10.12206/j.issn.1006-0111.202004030
    [6] 王玉鹏, 鲍婕.  异烟肼致肝损伤发病机制的研究进展 . 药学实践与服务, 2019, 37(4): 289-293. doi: 10.3969/j.issn.1006-0111.2019.04.001
    [7] 陈琪, 刘兴, 刘红亮.  右美托咪定用于神经阻滞的研究进展 . 药学实践与服务, 2018, 36(4): 289-292. doi: 10.3969/j.issn.1006-0111.2018.04.001
    [8] 姚媛, 周艺, 周婷婷.  抑郁症致病机制及中药治疗抑郁症的机制研究 . 药学实践与服务, 2018, 36(3): 193-197. doi: 10.3969/j.issn.1006-0111.2018.03.001
    [9] 刘彬, 盛苗苗, 朴贤美, 张妍.  腹腔术后抗粘连产品的研究进展 . 药学实践与服务, 2016, 34(4): 305-308,321. doi: 10.3969/j.issn.1006-0111.2016.04.005
    [10] 刘建清, 张晶, 赵佳丽, 宋洪涛.  纳米结构脂质载体促进难溶性药物口服吸收机制的研究进展 . 药学实践与服务, 2014, 32(4): 254-256,277. doi: 10.3969/j.issn.1006-0111.2014.04.004
    [11] 成彦琼, 张浩, 王威, 顾小飞, 刘爱军.  叶酸在心脑血管疾病防治中的机遇与挑战 . 药学实践与服务, 2013, 31(5): 330-333,350. doi: 10.3969/j.issn.1006-0111.2013.05.003
    [12] 舒菁菁, 李菲, 董雅芬, 金磊, 邹豪, 张川.  丹参素药理作用及机制的研究进展 . 药学实践与服务, 2012, 30(4): 266-268,298.
    [13] 张宁, 苏瑾, 金磊, 邹豪, 张川.  丹参素心血管作用机制的研究概况 . 药学实践与服务, 2009, 27(6): 404-406,447.
    [14] 于大海.  刺五加总皂苷对大鼠心肌缺血性再灌注的保护作用及机制研究 . 药学实践与服务, 2008, (3): 197-199,232.
    [15] 孙海英, 温燕.  舒血宁注射液引起急性荨麻疹 . 药学实践与服务, 2007, (4): 240-240.
    [16] 刘卫, 华南.  一氧化氮对动脉压力感受性反射的作用 . 药学实践与服务, 1999, (2): 77-78.
    [17] 李燕, 刘承烈, 管钧.  通脉丸对脑血管疾病疗效的临床观察 . 药学实践与服务, 1998, (1): 21-23.
    [18] 陈红, 余光宏, 魏梁锋, 朱铨英, 苏定冯.  高血压病与胰岛素抵抗 . 药学实践与服务, 1995, (6): 324-326,358.
    [19] 曾国钱, 孙笃新, 芮耀诚.  白三烯与脑血管疾病 . 药学实践与服务, 1992, (2): 5-7.
    [20] FelixBochner.  阿司匹林在脑血管疾病中的应用(连载之三) . 药学实践与服务, 1984, (3): 16-17.
  • 加载中
计量
  • 文章访问数:  3040
  • HTML全文浏览量:  880
  • PDF下载量:  1480
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-12-26
  • 修回日期:  2017-03-20

心脑血管疾病的治疗新策略:激活压力感受性反射

doi: 10.3969/j.issn.1006-0111.2017.04.002

摘要: 我国心脑血管疾病的发病人数和死亡人数持续升高,动脉压力感受性反射(arterial baroreflex, ABR)功能受损与许多心脑血管疾病(如高血压、心衰等)的发生、发展密切相关。美国CVRx公司研发的Barostim neoTM仪器可以实现慢性刺激颈动脉窦处的压力感受器,激活压力反射,从而降低血压和心率,用于治疗顽固性高血压、心衰、终末期肾损伤等疾病。其治疗疾病的主要机制是抑制交感神经系统和肾素-血管紧张素系统,增强迷走神经的活动,进而改善压力感受性反射敏感性(baroreflex sensitivity, BRS)和心率变异性,恢复关键脏器的结构和功能。

English Abstract

张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略:激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
引用本文: 张丽丽, 刘爱军, 陈磊, 宋洪涛. 心脑血管疾病的治疗新策略:激活压力感受性反射[J]. 药学实践与服务, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
Citation: ZHANG Lili, LIU Aijun, CHEN Lei, SONG Hongtao. New strategy for cardio-cerebrovascular diseases: baroreflex activation therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(4): 294-297,345. doi: 10.3969/j.issn.1006-0111.2017.04.002
参考文献 (34)

目录

    /

    返回文章
    返回